Array Biopharma Inc.

Genentech, Inc.

Jonas Grina

Li Ren

David A Moreno

James F Blake

Huifen Chen

Mark Joseph Chicarelli

John Joseph Gaudino

Ellen Ruth Laird

Jacob Bradley Schwarz

Peter J Mohr

Kirk D Robarge

Brad Newhouse

Aihe Zhou

Rustam Ferdinand Garrey

Joseph P Lyssikatos

Alexandre Joseph Buckmelter

Bainian Feng

George T Topalov

Wendy B Young

Simon Mathieu

Janet Gunzner

Joachim Rudolph

Zhaoyang Wen

Mike Welch

Steven Mark Wenglowsky

Kateri Ahrendt

Joshua D Hansen

Kim Malesky

Josh Hansen

Alan G Olivero

Jeongbeob Seo

Hongqi Tian

Kateri A Ahrendt

Jason De Meese

Paul Lunghofer

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazole [3, 4-B] pyridine Raf inhibitors

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Raf inhibitor compounds and methods of use thereof

Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Imidazopyrazines as Raf inhibitor compounds

Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

RAF inhibitor compounds and methods

Growing community of inventors

Boulder, CO, United States of America

Jonas Grina